Osimertinib
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Osimertinib
Osimertinib
Summary
The TxGNN model has no candidate with a score of 0.99 or higher for Osimertinib, so there is currently no new predicted indication. The recorded uses for this drug are listed below.
Quick overview
| Item | Content |
|---|---|
| Known uses recorded for this drug | 0 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 11620N | Tagrisso | Tablet 40 mg | Valid |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (EGFR tyrosine kinase inhibitor) |
| Myelosuppression Risk | Haematological toxicity (including thrombocytopenia) is reported in the literature; please refer to the Product Information (PI) warnings and precautions |
| Emetogenicity Classification | Please refer to the PI warnings and precautions |
| Monitoring Items | Full blood count is reasonable given reported haematological toxicity; cardiac monitoring is suggested by the reported cardiotoxicity (including QT prolongation and reduced LVEF); confirm against the PI |
| Handling Protection | Please refer to the PI warnings and precautions |
Safety Considerations
- Drug Interactions: The interaction query returned 100 interactions, 20 of which were listed.
- Major: clarithromycin, dolasetron, palonosetron, levofloxacin.
- Moderate (selected): famotidine, cimetidine, dexamethasone, aprepitant, loperamide, alosetron, empagliflozin, miconazole, metreleptin, and several laxatives and bowel-preparation agents (bisacodyl, picosulfuric acid, polyethylene glycol, sodium sulfate, lactitol, lactulose).
- Minor: metronidazole.
- Literature-reported risks:
- Cardiotoxicity (heart failure, cardiomyopathy, QT prolongation, atrial fibrillation).
- Thrombotic events (pulmonary embolism, splenic infarction).
- Interstitial lung disease.
Please refer to the TGA-approved Product Information (PI) for official warnings and contraindications, as these were not available in the data compiled for this report.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.